Health Professionals

Welcome to our dedicated resource page for GPs and Travel Health Professionals. Here, you can find valuable information and data about Travelan®.

To request patient handouts for Travelan®, please contact us.

Travelan Otto et al 2011

Diarrhea is a common affliction of travelers especially, those who visit less-developed countries [1,2]. Between 20% and 70% of visitors to such countries suffer from diarrhoea, which in approximately 50% of cases is caused by strains of enterotoxigenic Escherichia coli

Download Travelan Otto et al 2011 (145kb PDF)

Travelan GP Brochure

Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting Travellers’ Diarrhoea. The active ingredient in Travelan® is hyperimmune bovine colostrum enriched with Anti-E. coli antibodies. When taken with meals, Travelan® binds to Diarrhoeacausing bacteria and prevents colonisation and the pathology associated with Travellers’ Diarrhoea.

Download Travelan GP Brochure (6.2mb PDF)

Travelan Studies - All the latest research

Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhoea in up to 90% of volunteers

Diarrhea is a common affliction of travelers especially, those who visit less-developed countries. Between 20% and 70% of visitors to such countries suffer from diarrhea, which in approximately 50% of cases is caused by strains of enterotoxigenic Escherichia coli (ETEC).

View the study

Travelan as a broad Spectrum anti-bacterial

US Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveller’s diarrhoea.

Download the study (266kb PDF)

Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveler’s diarrhea

US Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveler’s diarrhea

Download the study (266kb PDF)

Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals compared to placebo and demonstrated a significant clinical benefit

Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completed.

Download the study (1mb PDF)

Travelan® able to bind and was reactive to 60 clinical isolates of each bacteria, Campylobacter, ETEC, and Shigella

The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand.

Download the study (126kb PDF)

Efficacy of hyperimmune bovine colostrum against shigellosis in rhesus macaque (Macaca mulatta), and bioactivity of HBC against common enteric pathogens

Infectious diarrhoea is a World Health Organization public health priority area due to the lack of effective vaccines and an accelerating global antimicrobial resistance crisis.